ϟ
DOI: 10.1158/1541-7786.22514668
¤ OpenAccess: Green
This work has “Green” OA status. This means it may cost money to access on the publisher landing page, but there is a free copy in an OA repository.
Figure S1-S7 from Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i>-Mutant Non–Small Cell Lung Cancer Cells
Kei Namba,Kazuhiko Shien,Yuta Takahashi,Hidejiro Torigoe,Hiroki Sato,Takahiro Yoshioka,Tatsuaki Takeda,Eisuke Kurihara,Yusuke Ogoshi,Hiromasa Yamamoto,Junichi Soh,Shuta Tomida,Shinichi Toyooka
Osimertinib
Cell culture
Cancer research
2023
<p>Figure S1. Copy numbers of YES1 in osimertinib-resistant cell lines. Figure S2. PARP and MET expressions in MET-amplified osimertinib-resistant cell lines. Figure S3. Relative ALDH1A1 and ABCB1 expression levels using qRT-PCR in NSCLC EGFR-mutant cell lines and their corresponding osimertinib-resistant cell lines. Figure S4. Expressions of AXL protein in NSCLC EGFR-mutant cell lines and their corresponding osimertinib-resistant cell lines. Figure S5. Copy numbers of AXL in osimertinib-resistant cell lines. Figure S6. siRNA and combined drug treatment studies in HCC4006 and HCC4006 resistant cells. Figure S7. Combined treatment with AXL knockdown and osimertinib in H1975 and H1975 resistant cells.</p>
Loading...
- MLA
- APA
- Chicago
- IEEE
- Harvard
- BibTeX
Cite this:
Generate Citation
“Figure S1-S7 from Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i>-Mutant Non–Small Cell Lung Cancer Cells” is a paper by Kei Namba Kazuhiko Shien Yuta Takahashi Hidejiro Torigoe Hiroki Sato Takahiro Yoshioka Tatsuaki Takeda Eisuke Kurihara Yusuke Ogoshi Hiromasa Yamamoto Junichi Soh Shuta Tomida Shinichi Toyooka published in 2023. It has an Open Access status of “green”. You can read and download a PDF Full Text of this paper here.